Invisible ink could replace permanent tattoos for radiation therapy
NCT ID NCT07095114
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests a special ink called Magic Ink that is only visible under UV light, used to mark the skin for daily radiation treatment in breast cancer patients. The goal is to see if it is as safe and effective as standard permanent tattoo ink, while being less noticeable. Thirty women with early-stage breast cancer will receive the Magic Ink tattoo and be followed for side effects and ease of treatment setup.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Magic Ink (UV-visible tattoo ink)
- What this could lead to
- If it works, this could make radiation treatment setup easier and less painful, while improving body image by hiding the tattoo marks.
- What could go wrong
- This is a small early-phase study with only 30 participants, so results may not apply to everyone. The ink might not stay visible or could cause skin reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Participant must have histologically or cytologically confirmed stage 0 ductal carcinoma in situ (DCIS), I, II or III breast cancer and be planning to undergo radiation therapy (RT) after surgery * Participants must be 18 years of age or older * Participant must be able to understand a written informed consent document and be willing to sign it * Participant must be assigned female at birth * Participant must have a Karnofsky performance score of greater than or equal to 70% * Women of child bearing potential must agree to avoid becoming pregnant through defined periods during the course of RT and must meet one of the following: * Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy * Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation * Agree to practice true abstinence from sexual intercourse * Not in a sexual relationship in which the may become pregnant (i.e., same-sex relationship) * If they are childbearing potential, agree to use at least one highly effective and at least one additional method of contraception. * For the first six participants only: Participant must have a Fitzpatrick Skin Tone Scale of 5 or 6 Exclusion Criteria: * Participants who have received prior radiation treatment to the affected breast. * Participants with a history of allergic reaction or hypersensitivity attributed to any tattoo ink * Participants with active chronic skin diseases such as psoriasis. Participants with inactive or controlled skin diseases are eligible for this study * Participants that are pregnant or breastfeeding. If a participant wishes to participate in this study, breastfeeding should be discontinued * Participants with a BMI greater than 44.5 as calculated within six months prior to the starting of the study. If there are multiple BMI measurements available in the chart, the most recent will be used to determine eligibility.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ductal carcinoma in situ are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Five-Session therapy ease distress and calm stress biology in Late-Stage breast cancer?
- Microscope aims to spare breast cancer patients a second surgery
- Which technique best finds hidden breast tumors? large study puts localization methods to the test
- Donor nerve grafts put to the test for restoring feeling after mastectomy
- Can a Hormone-Binding protein predict breast cancer risk? trial tests tamoxifen and fasting
- Your genes may decide if breast cancer drug causes joint pain